Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 8, 2004, Pages 416-421

  Jaeger, C ^a   Eckhard, M ^a   Brendel, M D ^a   Bretzel, R G ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Brittle diabetes; Insulin allergy; Insulin antibodies; Insulin resistance; Insulin therapy

Indexed keywords

HEMOGLOBIN A1C; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INSULIN; INSULIN ANTIBODY; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; NEUTRAL INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN;

ADULT; AGED; ALGORITHM; ANTIBODY TITER; CASE REPORT; CONFERENCE PAPER; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; FEMALE; HUMAN; INSULIN TREATMENT; INTRACUTANEOUS TEST; MALE; PRIORITY JOURNAL; PRURITUS; TREATMENT PLANNING;

ADULT; ALGORITHMS; AUTOANTIBODIES; CASE-CONTROL STUDIES; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGIC TECHNIQUES; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN ANTIBODIES; MALE; MIDDLE AGED; SKIN TESTS;

EID: 4744352232     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821186     Document Type: Conference Paper

References (25)

1. Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care 2001; 24: 2000
2. Christiansen AH. Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methodological studies. Horm Metabol Res 1973; 5: 147-154
3. Discher T, Seipke G, Friedmann E, Velcovsky HG, Federlin K. Recurrent hypoglycemia in the insulin autoimmune syndrome. Dtsch Med Wochenschr 1990; 115: 1950-1955
4. Dixon K. Measurement of antibodies to insulin in serum. Clin Chem 1974; 20: 1275-1281
5. Eapen SS, Connor EL, Gern JE. Insulin desensitization with insulin lispro and an insulin pump in a 5-year-old child. Ann Allergy Asthma Immunol 2000; 18: 395-397
6. Federlin K. Diabetes mellitus and immunology - a manifold interrelation. Immun Infekt 1985; 13: 1893-1899
7. Francis AJ, Hanning I, Alberti KGGM. The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins. Diabetologia 1985; 28: 330-334
8. Galloway JA, deShazo RD. Complications of insulin treatment. In: Ellenberg M, Rifkin H (Eds). Diabetes Mellitus: Theory and Practice. New Hyde Park: NY Med Exam, 1990: 506-508
9. Ganz MG, Untermann T, Roberts M, Uy R, Sahgal S, Samter M, Grammer LC. Resistance and allergy to recombinant human insulin. J Allergy Clin Immunol 1990; 86: 45-52
10. Hobler H, Zoltobrocki M, Schernthaner G, Schnack C, Federlin K. Formation of protamine, insulin, and native NPH-human insulin antibodies in diabetic patients treated with NPH-human insulin. One year observation study. Diab Nutr Metab 1991; 4: 275-281
11. Jaeger C, Hatziagelaki E, Stroedter A, Becker F, Scherer S, Petzoldt R, Federlin K, Bretzel RG. The Giessen-Bad Oeynhausen family study: improved prediction of type 1 diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model. Exp Clin Endocrinol Diabetes 1999; 107: 496-505
12. Kerp L, Steinhilber S, Kasemir H. Ein Verfahren zum Nachweis insulin-bindender Antikörper durch Differentialadsorption. Klin Wschr 1966; 90: 806-814
13. Kumar D. Lispro analog for the treatment of generalized allergy to human insulin. Diabetes Care 1997; 20: 1337-1359
14. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and c-peptide in insulin treated diabetics. Diabetes 1977; 26: 22-29
15. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report. Diabetes Care 1997; 20: 71-73
16. Lohmann T, Kratzsch J, Kellner K, Witzigmann H, Hauss J, Paschke R. Severe hypoglycemia due to insulin autoimmune syndrome with insulin autoantibodies crossreactive to proinsulin. Exp Clin Endocrinol Diabetes 2001; 109: 245-248
17. Moriyama H, Nagata M, Fujihira K, Yamada K, Chowdhury SA, Chakrabarty S, Zhenzi J, Yasuda H, Ueda H, Yokono K. Treatment with human analog insulin glargine resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care 2001; 24: 411-412
18. Näf S, Esmatjes E, Recasens M, Valero A, Halperin I, Levy I, Gomis R. Continous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25: 634-635
19. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med 1997; 36: 575-578
20. Schernthaner. Immunogenicity and allergic potential of animal and human insulins. Diabetes Care 1993; 16: 155-165
21. Van Haeften TW, Heiling VJ, Gerich JE. Adverse effects of insulin antibodies on postprandial plasma glucose and insulin profiles in diabetic patients without immune insulin resistance. Implications for intensive insulin regimens. Diabetes 1987; 36: 305-309
22. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 1989; 12: 641-648
23. Velcovsky HG, Federlin K. Insulin-specific IgG and IgE antibody response in type 1 diabetic subjects exclusively treated with human insulin (recomibinant DNA). Diabetes Care 1982; 5: 126-128
24. Von Kriegstein E, Schatz H. Insulin. In: Schatz H (ed). Diabetologie kompakt, Grundlagen und Praxis. 2nd ed. Berlin, Wien: Blackwell, 2002: 86-101
25. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48: 460-468